The short version of c-Met receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-26 and is reviewed periodically as new material appears.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Among psychotropic drugs, chlorpromazine is known to cause cholestatic hepatitis. Tricyclic antidepressants (imipramine, amitriptyline) and SSRIs (duloxetine) causing cholestasis have also been reported. Anti-inflammatory drugs with cholestatic potential include the immunosuppressant azathioprine, which has been reported to cause fatal cholestatic hepatitis, and the NSAID diclofenac.
== Toxicity == The biological function of TsPep2 is not clear yet, except from a small displacement on the 125I-KTX binding site on rat brain synaptosomes. However, it has been shown that this peptide is not toxic to mice. The LD50 of TsPep2 is currently unknown.
Acute intermittent porphyria Adrenoleukodystrophy (Schilder's disease) Alkaptonuria Aminolevulinic acid dehydratase deficiency porphyria (Doss porphyria, plumboporphyria) B-mannosidase deficiency Carotenosis Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome (CADASIL syndrome) Cerebrotendinous xanthomatosis Citrullinemia Congenital erythropoietic porphyria (Gunther's disease) Diabetic bulla (bullosis diabeticorum, bullous eruption of diabetes mellitus) Diabetic cheiroarthropathy Diabetic dermopathy (shin spots) Dystrophic calcinosis cutis Eruptive xanthoma Erythropoietic protoporphyria Fabry disease (Anderson–Fabry disease, angiokeratoma corporis diffusum) Familial alpha-lipoprotein deficiency (Tangier disease) Familial amyloid polyneuropathy Familial apoprotein CII deficiency Familial combined hyperlipidemia (multiple-type hyperlipoproteinemia) Familial defective apolipoprotein B-100 Familial dysbetalipoproteinemia (broad beta disease, remnant removal disease) Familial hypertriglyceridemia Farber disease (fibrocytic dysmucopolysaccharidosis, lipogranulomatosis) Fucosidosis Gaucher's disease Gout (podagra, urate crystal arthropathy, urate deposition disease) Hartnup disease (pellagra-like dermatosis) Hemodialysis-associated amyloidosis Hepatoerythropoietic porphyria Hereditary coproporphyria Hereditary gelsolin amyloidosis Heredofamilial amyloidosis Hunter syndrome Hurler syndrome (gargoylism, mucopolysaccharidosis type I) Hurler–Scheie syndrome (mucopolysaccharidosis type I H-S) Hyaluronidase deficiency (mucopolysaccharidosis type IX) Iatrogenic calcinosis cutis Idiopathic scrotal calcinosis (idiopathic calcified nodules of the scrotum) Lafora disease Lesch–Nyhan syndrome (juvenile gout) Lichen amyloidosis Limited joint mobility Lipoid proteinosis (hyalinosis cutis et mucosae, Urbach–Wiethe disease) Lipoprotein lipase deficiency (chylomicronemia, chylomicronemia syndrome) Macular amyloidosis Maroteaux–Lamy syndrome (mucopolysaccharidosis type VI) Medication-induced hyperlipoproteinemia Metastatic calcinosis cutis Milia-like calcinosis Morquio's disease (mucopolysaccharidosis type IV) Necrobiosis lipoidica (necrobiosis lipoidica diabeticorum) Niemann–Pick disease Nodular amyloidosis Nodular xanthoma Normolipoproteinemic xanthomatosis Obstructive liver disease (xanthomatous biliary cirrhosis) Ochronosis Osteoma cutis Palmar xanthoma Phenylketonuria Phytosterolemia (sitosterolemia) Porphyria cutanea tarda Primary cutaneous amyloidosis Primary systemic amyloidosis Prolidase deficiency Pseudoporphyria (pseudoporphyria cutanea tarda) Sanfilippo syndrome Scheie syndrome (mucopolysaccharidosis type I S) Secondary cutaneous amyloidosis Secondary systemic amyloidosis Sialidosis Sly syndrome (mucopolysaccharidosis type VII) Subepidermal calcified nodule (solitary congenital nodular calcification, Winer's nodular calcinosis) Transient erythroporphyria of infancy (purpuric phototherapy-induced eruption) Traumatic calcinosis cutis Tuberoeruptive xanthoma (tuberous xanthoma) Tumoral calcinosis Variegate porphyria (mixed hepatic porphyria, mixed porphyria, South African genetic porphyria, South African porphyria) Verruciform xanthoma Waxy skin Wilson's disease (hepatolenticular degeneration) Xanthelasma palpebrarum (xanthelasma) Xanthoma diabeticorum Xanthoma planum (plane xanthoma) Xanthoma striatum palmare Xanthoma tendinosum (tendinous xanthoma) Xanthoma tuberosum
Sources: en.wikipedia.org
== Diagnosis == The most conclusive test for a patient with a potential neurofibrosarcoma is a tumor biopsy (taking a sample of cells directly from the tumor itself). MRIs, X-rays, CT scans, and bone scans can aid in locating a tumor and/or possible metastasis.
=== Amino acid properties and environmental conditions === Amino acids commonly used for amino acid dating analysis are leucine, aspartic acid, valine, glutamic acid, and diastereomer isoleucine. The properties of the amino acid(s) chosen for analysis influence what kind of dating can be performed. Amino acid interconversion reactions happen at a variety of speeds: aspartic acid racemizes very quickly and hence is used for recent samples where high resolution is important, while valine and leucine take much longer to racemize and are more appropriate for older fossils. Additionally, these reaction rates are sensitive to temperature, to a degree depending on the specific interconversion reaction. The racemization rate of aspartic acid varies with small changes in temperature, while valine's racemization rate is less temperature dependent. Besides higher temperatures accelerating interconversion reactions, other environmental variables also impact reaction rates. Wetter environments produce faster reaction rates, and interconversion reactions may be catalyzed by the presence of acids, bases, or metal cations. The chosen host organisms or taxa also introduce bias into age estimates. Amino acids which are bound within peptides interconvert more slowly than those which are free or are occupying the terminal position of peptide chains. The degree of hydrolysis of peptides (and therefore the speed at which equilibrium approaches) increases with fossil age.
{\displaystyle {\begin{aligned}K_{M}\ &{\stackrel {\mathrm {def} }{=}}\ {\frac {k_{2}+k_{-1}}{k_{1}}}\approx K_{D}\\V_{\max }\ &{\stackrel {\mathrm {def} }{=}}\ k_{cat}{\ce {[E]}}_{tot}\end{aligned}}}
Sources: en.wikipedia.org
The lactate racemase enzyme (Lar) (EC 5.1.2.1) interconverts the D- and L-enantiomers of lactic acid. It is classified under the isomerase, racemase, epimerase, and enzyme acting on hydroxyl acids and derivatives classes of enzymes. It is found in certain halophilic archaea, such as Haloarcula marismortui, and in a few species of bacteria, such as several Lactobacillus species (which produce D- and L-lactate) including Lactobacillus sakei, Lactobacillus curvatus, and Lactobacillus plantarum, as well as in non-lactic acid bacteria such as Clostridium beijerinckii. The gene encoding lactate racemase in L. plantarum was identified as larA and shown to be associated with a widespread maturation system involving larB, larC1, larC2, and larE. The optimal pH for its activity is 5.8-6.2 in L. sakei.
=== CaMK2D === CaMK2D appears in both neuronal and non-neuronal cell types. It is characterized particularly in many tumor cells, such as a variety of pancreatic, leukemic, breast and other tumor cells. found that CaMK2D is downregulated in human tumor cells.
To gather enough information for diagnosis, the measurement of potassium must be repeated, as the elevation can be due to hemolysis in the first sample. The normal serum level of potassium is 3.5 to 5 mmol/L. Generally, blood tests for kidney function (creatinine, urea), glucose and occasionally creatine kinase and cortisol are performed. Calculating the trans-tubular potassium gradient has been recommended as a method of identifying whether or not aldosterone is acting; however, the measurement properties of this test were never described and some experts doubt the usefulness of this approach. In the medical history, the presence of known kidney disease, diabetes mellitus, and the use of certain medications (e.g., potassium-sparing diuretics) are important issues. Electrocardiography (ECG) may be performed to determine if there are ECG changes, tachy- or brady-arrythmias.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.